AZD-0120 is under clinical development by Gracell Biotechnologies and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AZD-0120’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AZD-0120 overview

GC0-12 is under development for the treatment of advanced relapsed/refractory multiple myeloma, newly diagnosed multiple myeloma, refractory generalized myasthenia gravis, B-cell non-Hodgkin's lymphoma, primary mediastinal b-cell lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, marginal zone b-cell lymphoma, mantle cell lymphoma and systemic lupus erythematosus. The therapy constitutes of genetically manipulated T cells which express dual chimeric antigen receptor targeting tumor cells expressing B-cell maturation antigen (BCMA) and CD19 chimeric antigen receptors. It is developed based on FasTCAR platform. It is administered through intravenous route.

Gracell Biotechnologies overview

Gracell Biotechnologies, a subsidiary of AstraZeneca Plc, is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative cell therapies aimed at addressing unmet medical needs in the treatment of cancer and autoimmune diseases. The company is headquartered in Shanghai, China.

For a complete picture of AZD-0120’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.